Patent: 9,957,321
✉ Email this page to a colleague
Summary for Patent: 9,957,321
Title: | Anti-IL-6 antibodies for the treatment of oral mucositis |
Abstract: | The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat mucositis (e.g., oral mucositis) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of mucositis, including oral mucositis. |
Inventor(s): | Smith; Jeffrey T. L. (Bellevue, WA), Garcia-Martinez; Leon F. (Woodinville, WA), Feldhaus; Andrew L. (Lynnwood, WA) |
Assignee: | ALDERBIO HOLDINGS LLC (Las Vegas, NV) |
Application Number: | 14/672,392 |
Patent Claims: | see list of patent claims |
Details for Patent 9,957,321
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2030-11-23 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2030-11-23 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2030-11-23 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2030-11-23 |
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | 11/14/2014 | ⤷ Try a Trial | 2030-11-23 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 10/12/2004 | ⤷ Try a Trial | 2030-11-23 |
Wyeth Pharmaceuticals Llc | MYLOTARG | gemtuzumab ozogamicin | For Injection | 761060 | 09/01/2017 | ⤷ Try a Trial | 2030-11-23 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |